Illumina’s announces new sequencers: NovaSeq Series

Illumina announced new sequencers, NovaSeq 5000 and 6000, that could potentially reduces the cost of human genome sequencing to $100 in the future. The NovaSeq sequencing systems, which are built from the ground up, offers scalability and flexibility for any type of sequencing, either large scale or targeted sequencing. NovaSeq 5000 and 6000 NovaSeq 5000 […]

Illumina Sues Oxford Nanopore

In case you missed it, Illumina announced that it is Oxford Nanopore Technologies for violating Illumina’s two patents on nanopore sequencing in Oxford Nanopore’s MinION and PromethION devices. Illumina press release says that The lawsuits are based on U.S. Patent Nos. 8,673,550 and 9,170,230, which are entitled “MSP NANOPORES AND RELATED METHODS.”Illumina has exclusively licensed the […]

Illumina Announces MiniSeq, a new benchtop sequencer

Illumina announced MiniSeq, a new benchtop sequencing system, at this year’s JPM. With MiniSeq, Illumina hopes to offer NGS workflow solution for every lab. MiniSeq is priced at $49,500 USD, to make it easy for any laboratory to adopt NGS. The MiniSeq System is expected to be available early in the first quarter of 2016. MiniSeq […]

Illumina Announces Three New Sequencers at JPM 2015: HiSeq X Five, HiSeq 3000/4000, and NextSeq 550

Illumina welcomed the new year with three/four new sequencing systems with a wide range of sequencing capabilities. This year Illumina mainly focused of HiSeq X and HiSeq systems and announced new HiSeq X Five, HiSeq 3000/4000, and, NextSeq 550.  Announcing the new set of sequencers, Jay Flatley, Illumina’s Chief Executive Officer, said Illumina technology has […]

Illumina Acquires Myraqa, a Regulatory Firm

Illumina announced that it acquired Myraqa, a Redwood Shores, California based regulatory firm specializing in In Vitro Diagnostics and companion diagnostics. Myraqa was founded in 1998 by Mya Thomae, RAC, CQA. Myraqa was formerly known as Mya Thomae Consulting. Announcing the acquisition, Illumina said the acquisition will bolster Illumina’s capabilities for clinical readiness and help […]